Destiny Pharma PLC Director Dealing (5504B)

TIDMDEST

RNS Number : 5504B

Destiny Pharma PLC

10 June 2021

Destiny Pharma plc

("Destiny Pharma" or the "Company")

Director Dealing

Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces that it was notified on 10 June 2021 that on that same day, Dr William Love, Chief Scientific Officer of the Company, sold 350,000 ordinary shares of 1 pence in the Company ("Ordinary Shares") at a price of 120 pence.

Following the sale, Dr William Love's beneficial interest in the Company is 6,509,500 Ordinary Shares, representing 10.87 per cent. of the total issued share capital. Dr Love confirms that he does not intend to sell any further Ordinary Shares for the foreseeable future, that is until 2023 at the earliest.

Enquiries:

 
                                                      [phone] 
  Destiny Pharma plc                                   440 
  Neil Clark, CEO 
   Shaun Claydon, CFO 
  finnCap Limited - Nominated Adviser and Joint 
   Broker                                             [phone] 
  Geoff Nash / Kate Bannatyne (Corporate Finance) 
   Alice Lane (ECM) 
  WG Partners LLP - Joint Broker                      [phone] 
  Nigel Barnes / Claes Spång / Nigel Birks 
  Optimum Strategic Communications                    [phone] 
  Mary Clark / Shabnam Bashir / Manel Mateus 
 

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

For further information, please visit https://www.destinypharma.com

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
            1.   Details of the person discharging managerial responsibilities 
                  / person closely associated 
 a)              Name                             Dr William Love 
                -------------------------------  -------------------------------------- 
            2.   Reason for the Notification 
                ----------------------------------------------------------------------- 
 a)              Position/status                  Chief Scientific Officer 
                -------------------------------  -------------------------------------- 
 b)              Initial notification/Amendment   Initial Notification 
                -------------------------------  -------------------------------------- 
 3.              Details of the issuer, emission allowance market participant, 
                  auction platform, auctioneer or auction monitor 
                ----------------------------------------------------------------------- 
 a)              Name                             Destiny Pharma plc 
                -------------------------------  -------------------------------------- 
 b)              LEI                              213800O9WH9Z38EHAC95 
                -------------------------------  -------------------------------------- 
 4.              Details of the transaction(s): section to be repeated 
                  for (i) each type of instrument; (ii) each type of transaction; 
                  (iii) each date; and (iv) each place where transactions 
                  have been conducted 
                ----------------------------------------------------------------------- 
 a)              Description of the               Ordinary shares of 1p each ("Ordinary 
                  Financial instrument,            Shares") 
                  type of instrument 
                -------------------------------  -------------------------------------- 
                 Identification code              DEST GB00BDHSP575 
                -------------------------------  -------------------------------------- 
 b)              Nature of the transaction        Sale of Ordinary Shares 
                -------------------------------  -------------------------------------- 
 c)              Price(s) and volume(s)                    Price(s)     Volume(s) 
                                                    Sold    120 pence    350,000 
                                                           -----------  ---------- 
                -------------------------------  -------------------------------------- 
 d)              Aggregated information: 
                   *    Aggregated volume           See 4c) above 
 
 
                   *    Price 
                -------------------------------  -------------------------------------- 
 e)              Date of the transaction          10 June 2021 
                -------------------------------  -------------------------------------- 
 f)              Place of the transaction         London Stock Exchange, AIM Market 
                                                   (XLON) 
                -------------------------------  -------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFLFEERLIILIL

(END) Dow Jones Newswires

June 10, 2021 12:00 ET (16:00 GMT)